creatine has been researched along with 2019 Novel Coronavirus Disease in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with chronic kidney disease and type 2 diabetes have a higher risk of developing pneumonia as well as an increased risk of severe COVID-19-associated adverse events and mortality." | 3.11 | Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis. ( Agarwal, R; Ahlers, C; Anker, SD; Brinker, M; Filippatos, GS; Joseph, A; Lambelet, M; Lawatscheck, R; Pitt, B; Rossing, P; Ruilope, LM, 2022) |
| "Low muscle mass and malnutrition are prevalent conditions among adults of all ages, with any body weight or body mass index, and with acute or chronic conditions, including COVID-19." | 2.82 | Advances in muscle health and nutrition: A toolkit for healthcare professionals. ( Atherton, PJ; Chew, STH; Gonzalez, MC; Landi, F; Molinger, J; Prado, CM; Ruck, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 9 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lorè, NI | 1 |
| De Lorenzo, R | 1 |
| Rancoita, PMV | 1 |
| Cugnata, F | 1 |
| Agresti, A | 1 |
| Benedetti, F | 1 |
| Bianchi, ME | 1 |
| Bonini, C | 1 |
| Capobianco, A | 1 |
| Conte, C | 1 |
| Corti, A | 1 |
| Furlan, R | 1 |
| Mantegani, P | 1 |
| Maugeri, N | 1 |
| Sciorati, C | 1 |
| Saliu, F | 1 |
| Silvestri, L | 1 |
| Tresoldi, C | 1 |
| Ciceri, F | 1 |
| Rovere-Querini, P | 1 |
| Di Serio, C | 1 |
| Cirillo, DM | 1 |
| Manfredi, AA | 1 |
| Prado, CM | 1 |
| Landi, F | 1 |
| Chew, STH | 1 |
| Atherton, PJ | 1 |
| Molinger, J | 1 |
| Ruck, T | 1 |
| Gonzalez, MC | 1 |
| Bashir, S | 1 |
| Ahmad, A | 1 |
| Iqbal, H | 1 |
| Nasir, S | 1 |
| Nawaz, KH | 1 |
| Ayub, Z | 1 |
| Bozkurt, F | 1 |
| Çoşkun, Ö | 1 |
| Yeleç, S | 1 |
| Bekçibaşı, M | 1 |
| Asena, M | 1 |
| Bağlı, İ | 1 |
| Pitt, B | 1 |
| Agarwal, R | 1 |
| Anker, SD | 1 |
| Ruilope, LM | 1 |
| Rossing, P | 1 |
| Ahlers, C | 1 |
| Brinker, M | 1 |
| Joseph, A | 1 |
| Lambelet, M | 1 |
| Lawatscheck, R | 1 |
| Filippatos, GS | 1 |
| Xing, Y | 1 |
| Sun, Y | 1 |
| Tang, M | 1 |
| Huang, W | 1 |
| Luo, J | 1 |
| Ma, Q | 1 |
| Thomas, T | 1 |
| Stefanoni, D | 1 |
| Reisz, JA | 1 |
| Nemkov, T | 1 |
| Bertolone, L | 1 |
| Francis, RO | 1 |
| Hudson, KE | 1 |
| Zimring, JC | 1 |
| Hansen, KC | 1 |
| Hod, EA | 1 |
| Spitalnik, SL | 1 |
| D'Alessandro, A | 1 |
| Gul, M | 1 |
| Kaynar, M | 1 |
| Yildiz, M | 1 |
| Batur, AF | 1 |
| Akand, M | 1 |
| Kilic, O | 1 |
| Goktas, S | 1 |
| Ostojic, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Dia[NCT02540993] | Phase 3 | 5,734 participants (Actual) | Interventional | 2015-09-17 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus a[NCT02545049] | Phase 3 | 7,352 participants (Actual) | Interventional | 2015-09-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to the first occurrence of a hospitalization event were evaluated. Number of participants with the event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 1263 |
| Placebo | 1321 |
Count of participants and time from randomization until death due to any cause were evaluated. Number of participants with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table. (NCT02540993)
Timeframe: From randomization up until death due to any cause, or censoring at the end of the study visit, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 219 |
| Placebo | 244 |
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. (NCT02540993)
Timeframe: From baseline up until Month 4
| Intervention | Ratio (Least Squares Mean) |
|---|---|
| Finerenone | 0.655 |
| Placebo | 0.952 |
Count of participants and time from randomization to the first occurrence of the key secondary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the key secondary CV composite endpoint, or censoring at the end of the study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 367 |
| Placebo | 420 |
Count of participants and time from randomization to the first occurrence of the secondary renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the composite primary endpoint, or censoring at the end of the study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 252 |
| Placebo | 326 |
Count of participants and time from randomization to the first occurrence of the primary renal composite outcome, onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 504 |
| Placebo | 600 |
Number of participants with first occurrence of a hospitalization event were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 1573 |
| Placebo | 1605 |
Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table. (NCT02545049)
Timeframe: From randomization up until death due to any cause, or censoring at the end of the study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 333 |
| Placebo | 370 |
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. (NCT02545049)
Timeframe: From baseline up until Month 4
| Intervention | Ratio (Least Squares Mean) |
|---|---|
| Finerenone | 0.624 |
| Placebo | 0.922 |
Number of participants with the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 458 |
| Placebo | 519 |
Number of participants with first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 108 |
| Placebo | 139 |
Number of participants with first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 350 |
| Placebo | 395 |
2 reviews available for creatine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Advances in muscle health and nutrition: A toolkit for healthcare professionals.
Topics: Adult; Amino Acids; Amino Acids, Branched-Chain; COVID-19; Creatine; Delivery of Health Care; Dietar | 2022 |
Diagnostic and Pharmacological Potency of Creatine in Post-Viral Fatigue Syndrome.
Topics: Biomarkers; Brain; COVID-19; Creatine; Dietary Supplements; Fatigue Syndrome, Chronic; Humans; Muscl | 2021 |
1 trial available for creatine and 2019 Novel Coronavirus Disease
6 other studies available for creatine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study.
Topics: Biomarkers; C-Reactive Protein; Chemokine CXCL10; Comorbidity; Coronary Artery Disease; COVID-19; Cr | 2021 |
Can blood glucose levels predict biochemical and haematological abnormalities in COVID -19 patients - Experience from a tertiary care hospital in Balochistan.
Topics: Adult; Alanine Transaminase; Blood Glucose; C-Reactive Protein; Cohort Studies; COVID-19; Creatine; | 2022 |
Evaluation of clinical and laboratory findings in severe group COVID-19 pregnants without comorbidity.
Topics: Comorbidity; COVID-19; Creatine; Female; Ferritins; Humans; Oxidoreductases; Pregnancy; Retrospectiv | 2022 |
Variables Associated with 30-Day Mortality in Very Elderly COVID-19 Patients.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; COVID-19; Creatine; Humans; Retrospec | 2023 |
COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status.
Topics: Adult; Aged; Amino Acids; Betacoronavirus; Blood Glucose; Case-Control Studies; Coronavirus Infectio | 2020 |
The Increased Risk of Complicated Ureteral Stones in the Era of COVID-19 Pandemic.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Creatine; Emergency Service, Hospital; Fem | 2020 |